Skip to Content
 

VICC toll-free number 1-877-936-8422

Clinical Trials for Hematologic Cancers

41 Open Trials

    Trial Type Protocol No. &
    Open Date
    Summary

    Basic Science

    Leukemia

    VICCHEM1305

    04/02/2013

    Investigating Abnormal Signaling in Acute Myeloid Leukemia (AML)

    Basic Science

    Leukemia

    COGAALL08B1

    10/18/2010

    Classification of Newly Diagnosed Acute Lymphoblastic Leukemia (ALL)

    Basic Science

    Hematologic

    VICCBMT1008

    02/18/2010

    Skin or Gut Infiltrating Foxp3+ Cells and Their Association with Acute Graft-Versus-Host Disease Severity (deidentified)

    Basic Science

    Hematologic

    NMDPBMT0346

    07/09/2003

    Repository for National Donor Program (NMDP) Research Blood Samples.

    Diagnostic

    Leukemia

    ECOGHEMEAI141

    05/10/2016

    Early Assessment of Treatment Response in AML Using FLT PET/CT Imaging

    Other

    Leukemia

    VICCHEM14133

    11/11/2015

    Connect MDS and AML: The Myelodysplastic Syndromes (MDS) and Acute Myeloid Leukemia (AML) Disease Registry

    Other

    Myelodysplastic Syndrome

    VICCBMT1407

    04/17/2015

    A Multi-Center Biologic Assignment Trial Comparing Reduced Intensity Allogeneic Hematopoietic Cell Transplant to Hypomethylating Therapy or Best Supportive Care in Patients Aged 50-75 with Intermediate-2 and High Risk Myelodysplastic Syndrome

    Other

    Multiple Myeloma

    VICCHEM1470

    11/05/2014

    Prospective Observation of Cardiac Safety with Proteasome Inhibition (PROTECT)

    Other

    Hematologic

    VICCBMT1401

    08/29/2014

    Prospective Outcomes of Second-Line Therapy in Acute Graft-versus-Host Study Including ECP (POSTAGE)

    Other

    Hematologic

    VICCBMT1110

    11/02/2001

    Hematopoietic Stem Cell Transplantaion and Marrow Toxic Injuries (Registry)

    Supportive Care

    Hematologic

    VICCBMT1426

    11/10/2014

    Metabolic and CD4+ T Cell Dysregulation in Post-Transplant Diabetes Mellitus

    Supportive Care

    Leukemia
    Pediatric Leukemia

    COGACCL0933

    11/16/2011

    A Randomized Open-Label Trial of Caspofungin versus Fluconazole to Prevent Invasive Fungal Infections in Children Undergoing Chemotherapy for Acute Myeloid Leukemia (AML)

    Treatment

    Leukemia
    Multiple Myeloma

    VICCHEM1621

    09/16/2016

    An Open-Label, Multicenter Phase I Study to Characterize the Safety, Tolerability, Preliminary Anti-Tumor Activity, Pharmacokinetics and Maximum Tolerated Dose of BAY 1251152 in Patients with Advanced Hematological Malignancies

    Treatment

    Leukemia

    VICCHEM1654

    09/09/2016

    An Open-Label, Multi-Center, Expanded Treatment Protocol of Midostaurin (PKC412) in Adult Patients with Newly Diagnosed FMS-Like Tyrosine Kinase Receptor (FLT3) Mutated Acute Myeloid Leukemia (AML) Who are Eligible for Standard Induction and Consolidation Chemotherapy

    Treatment

    Lymphoma

    ECOGHEME4412

    08/18/2016

    A Phase I Study with an Expansion Cohort of the Combinations of Ipilimumab, Nivolumab and Brentuximab Vedotin in Patients with Relapsed/Refractory Hodgkin Lymphoma

    Treatment

    Hematologic

    VICCHEM1613

    08/02/2016

    A Phase 2b, Randomized, Double-blind, Placebo-controlled Study of NEOD001 in Previously Treated Subjects with Light Chain (AL) Amyloidosis who have Persistent Cardiac Dysfunction

    Treatment

    Hematologic
    Leukemia
    Lung
    Miscellaneous
    Small Cell

    VICCHEMP1615

    07/21/2016

    A Phase 1/2, Open-Label, Dose-Escalation/Dose-Expansion, Safety and Tolerability Study of INCB059872 in Subjects with Advanced Malignancies

    Treatment

    Lymphoma
    Miscellaneous

    VICCPHI1616

    06/08/2016

    A Phase 1 Open-Label Study of the Safety, Tolerability and Efficacy of KPT-9274, a Dual Inhibitor of PAK4 and NAMPT, in Patients with Advanced Solid Malignancies or Non-Hodgkin's Lymphoma

    Treatment

    Leukemia

    VICCHEM15113

    05/06/2016

    A Phase 1, Multicenter, Open-Label, Safety Study of AG-120 or AG-221 in Combination with Induction Therapy and Consolidation Therapy in Patients with Newly Diagnosed Acute Myeloid Leukemia with an IDH1 and/or IDH2 Mutation

    Treatment

    Leukemia
    Lymphoma
    Pediatric Leukemia
    Pediatric Lymphoma

    VICCPED1537

    04/28/2016

    T2014-001 A Phase I Trial of Temsirolimus (CC-779, Pfizer, Inc.) in Combination with Etoposide and Cyclophosphamide in Children with Relapsed Acute Lymphoblastic Leukemia and Non-Hodgkins Lymphoma

    Treatment

    Leukemia
    Pediatric Leukemia

    COGAAML1331

    04/28/2016

    A Phase III Study for Patients with Newly Diagnosed Acute Promyelocytic Leukemia (APL) using Arsenic Trioxide and All-Trans Retinoic Acid

    Treatment

    Multiple Myeloma

    VICCBMT1566

    04/21/2016

    Continued, Long-Term Follow-Up and Lenalidomide Maintenance Therapy for Patients Who Have Enrolled on BMT CTN 0702

    Treatment

    Hematologic

    VICCHEM1580

    03/11/2016

    A Phase 2, Prospective Study of PRM-151 in Subjects with Primary Myelofibrosis (PMF), Post - Polycythemia Vera MF (post-PV MF), or Post -Essential Thrombocythemia MF (post-ET MF)

    Treatment

    Colon
    Head/Neck
    Lung
    Lymphoma
    Melanoma
    Non Small Cell
    Ovarian
    Rectal

    VICCPHI1531

    03/01/2016

    A Phase 1/2 Study of the Safety, Tolerability, and Efficacy of Epacadostat Administered in Combination With Nivolumab in Select Advanced Cancers

    Treatment

    Leukemia

    VICCHEM1597

    02/17/2016

    A Phase 3 Open-label, Multicenter, Randomized Study of ASP2215 versus Salvage Chemotherapy in Patients with Relapsed or Refractory Acute Myeloid Leukemia (AML) with FLT3 Mutation

    Treatment

    Leukemia
    Pediatric Leukemia

    COGAALL1331

    02/01/2016

    Risk-Stratified Randomized Phase III Testing of Blinatumomab (IND# 117467, NSC#765986) in First Relapse of Childhood B-Lymphoblastic Leukemia (B-ALL)

    Treatment

    Multiple Myeloma

    VICCHEM15112

    01/11/2016

    A Phase 1/2 Open-label Study of the Safety, Tolerability and Efficacy of the Selective Inhibitor of Nuclear Export (SINE) Compound KPT-8602 in Patients with Relapsed/Refractory Multiple Myeloma

    Treatment

    Hematologic

    VICCHEM1565

    01/05/2016

    A Phase 3, Randomized, Multicenter, Double-Blind, Placebo-Controlled, 2-Arm, Efficacy and Safety Study of NEOD001 Plus Standard of Care vs. Placebo Plus Standard of Care in Subjects with Light Chain (AL) Amyloidosis

    Treatment

    Multiple Myeloma

    VICCHEM14131

    11/17/2015

    Phase 1b Study of Carfilzomib Administered Once Weekly in Combination with Lenalidomide and Dexamethasone in Subjects with Multiple Myeloma

    Treatment

    Lymphoma

    VICCHEM14125

    11/13/2015

    A Phase 1-2 Multi-Center Study Evaluating the Safety and Efficacy of KTE-C19 in Subjects with Refractory Aggressive Non-Hodgkin Lymphoma (NHL)

    Treatment

    Bladder
    Breast
    Hematologic
    Leukemia
    Lymphoma
    Multiple Myeloma
    Myelodysplastic Syndrome
    Pancreatic
    Urologic

    VICCHEMP1558

    10/09/2015

    A Phase 1a/1b, Open-Label, Dose-Escalation, Safety and Tolerability Study of INCB052793 in Subjects With Advanced Malignancies

    Treatment

    Multiple Myeloma

    VICCHEM1437

    09/29/2015

    A Randomized Phase III Study Comparing Conventional Dose Treatment Using a Combination of Lenalidomide, Bortezomib and Dexamethasone (RVD) to High-Dose Treatment with Peripheral Stem Cell Transplant in the Initial Management of Myeloma in Patients up to 65 Years of Age

    Treatment

    Multiple Myeloma

    VICCHEM1526

    07/01/2015

    A Phase 2b, Open-Label, Single-Arm Study of Selinexor (KPT-330) plus Low-Dose Dexamethasone in Patients with Multiple Myeloma Quad-Refractory to Previous Therapies

    Treatment

    Leukemia
    Lymphoma
    Pediatric Leukemia
    Pediatric Lymphoma

    COGAALL1231

    05/13/2015

    A Phase III Randomized Trial Investigating Bortezomib NSC# 681239; IND# 58443) on a Modified Augmented BFM (ABFM) Backbone in Newly Diagnosed T-Lymphoblastic Leukemia (T-ALL) and T-Lymphoblastic Lymphoma (T-LLy)

    Treatment

    Leukemia

    VICCHEM1505

    05/06/2015

    An Open-Label Phase I Dose-Escalation Study to Characterize the Safety, Tolerability, Pharmacokinetics, and Maximum Tolerated Dose of BAY 1143572 given in a Once-Daily or an Intermittent Dosing Schedule in Subjects with Advanced Acute Leukemia

    Treatment

    Lymphoma

    VICCHEM1490

    04/07/2015

    Phase 1/2 Open-label, Multiple-dose, Dose-escalation Study to Evaluate the Safety and Tolerability of IMO-8400 in Patients with Relapsed or Refractory Diffuse Large B-cell Lymphoma and MyD88 L265P Mutation

    Treatment

    Leukemia

    VICCHEM1423

    08/08/2014

    A Phase 3 Open-Label Randomized Study of Quizartinib (AC220) Monotherapy Versus Salvage Chemotherapy in Subjects with FLT3-ITD Positive Acute Myeloid Leukemia (AML) Refractory To or Relapsed After First-line Treatment With or Without Hematopoietic Stem Cell Transplantation (HSCT) Consolidation

    Treatment

    Lymphoma

    VICCHEM13105

    04/09/2014

    A Single-Arm, Open-Label Phase 2 Study of Nivolumab (BMS-936558) in Subjects with Relapsed or Refractory Follicular Lymphoma (FL)

    Treatment

    Leukemia

    VICCHEM1294

    02/25/2013

    A Phase 3, Randomized, Double-Blind, Placebo-Controlled Study to Compare Efficacy and Safety of Oral Azacitidine Plus Best Supportive Care Versus Best Supportive Care as Maintenance Therapy in Subjects with Acute Myeloid Leukemia in Complete Remission

    Treatment

    Lymphoma

    VICCHEM1146

    08/14/2012

    Ofatumumab in Combination with High Dose Cytarabine Chemoimmunotherapy for Patients with Newly Diagnosed Mantle Cell Lyjmphoma

    Treatment

    Hematologic

    VICCBMT1158

    10/20/2011

    A Multicenter Access and Distribution Protocol for Unlicensed Cryopreserved Cord Blood Units (CBUs) for Transplantation in Pediatric and Adult Patients with Hematologic Malignancies and other Indications


    Print this page for your doctor